Andrew B Janowski1, Holly Dudley2, David Wang3. 1. Department of Pediatrics, Washington University School of Medicine, St Louis, MO, United States. Electronic address: abjanowski@wustl.edu. 2. Department of Pediatrics, Washington University School of Medicine, St Louis, MO, United States. 3. Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, United States; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, United States.
Abstract
BACKGROUND: Recent recognition of invasive astrovirus infections, including encephalitis and viremia in humans, have highlighted the need for effective anti-astrovirus therapeutics. However, there is a paucity of data regarding the in vitro activity of broad-spectrum RNA antivirals against astroviruses, including ribavirin and favipiravir. OBJECTIVES: We quantified the EC50 values for ribavirin and favipiravir against two human astrovirus strains, astrovirus VA1 (VA1) and human astrovirus 4 (HAstV4). STUDY DESIGN: Caco-2 cells were infected with VA1 or HAstV4 in the presence of ribavirin or favipiravir (dose range 0.1-1000 μM), and the cells were maintained in media containing the drugs for 72 h. Viral RNA was extracted and quantified by qRT-PCR. As a surrogate for cytotoxicity, cellular adenosine triphosphate (ATP) from each drug treatment was also measured. RESULTS: VA1 replication was inhibited 10-100-fold by both ribavirin (EC50 = 154 μM) and favipiravir (EC50 = 246 μM). In contrast, ribavirin inhibited HAstV4 replication (EC50 = 268 μM) but favipiravir only reduced replication by 44% at the highest dose. Mild reductions in ATP (17-31%) was only observed at the highest concentration of ribavirin (1000 μM) and no significant decrease in ATP was detected for any concentration of favipiravir. CONCLUSIONS: Ribavirin inhibited both human astrovirus species and favipiravir was only active against VA1. In the future, the in vivo efficacy of these drugs could be tested with development of an animal model of human astrovirus infection.
BACKGROUND: Recent recognition of invasive astrovirus infections, including encephalitis and viremia in humans, have highlighted the need for effective anti-astrovirus therapeutics. However, there is a paucity of data regarding the in vitro activity of broad-spectrum RNA antivirals against astroviruses, including ribavirin and favipiravir. OBJECTIVES: We quantified the EC50 values for ribavirin and favipiravir against two human astrovirus strains, astrovirusVA1 (VA1) and human astrovirus 4 (HAstV4). STUDY DESIGN:Caco-2 cells were infected with VA1 or HAstV4 in the presence of ribavirin or favipiravir (dose range 0.1-1000 μM), and the cells were maintained in media containing the drugs for 72 h. Viral RNA was extracted and quantified by qRT-PCR. As a surrogate for cytotoxicity, cellular adenosine triphosphate (ATP) from each drug treatment was also measured. RESULTS:VA1 replication was inhibited 10-100-fold by both ribavirin (EC50 = 154 μM) and favipiravir (EC50 = 246 μM). In contrast, ribavirin inhibited HAstV4 replication (EC50 = 268 μM) but favipiravir only reduced replication by 44% at the highest dose. Mild reductions in ATP (17-31%) was only observed at the highest concentration of ribavirin (1000 μM) and no significant decrease in ATP was detected for any concentration of favipiravir. CONCLUSIONS:Ribavirin inhibited both human astrovirus species and favipiravir was only active against VA1. In the future, the in vivo efficacy of these drugs could be tested with development of an animal model of humanastrovirus infection.
Authors: M-L Frémond; P Pérot; E Muth; G Cros; M Dumarest; N Mahlaoui; D Seilhean; I Desguerre; C Hébert; N Corre-Catelin; B Neven; M Lecuit; S Blanche; C Picard; M Eloit Journal: J Pediatric Infect Dis Soc Date: 2015-07-12 Impact factor: 3.164
Authors: Wen Dang; Yuebang Yin; Yijin Wang; Wenshi Wang; Junhong Su; Dave Sprengers; Luc J W van der Laan; Krzysztof Felczak; Krzysztof W Pankiewicz; Kyeong-Ok Chang; Marion P G Koopmans; Herold J Metselaar; Maikel P Peppelenbosch; Qiuwei Pan Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191
Authors: Phenix Lan Quan; Thor A Wagner; Thomas Briese; Troy R Torgerson; Mady Hornig; Alla Tashmukhamedova; Cadhla Firth; Gustavo Palacios; Ada Baisre-De-Leon; Christopher D Paddock; Stephen K Hutchison; Michael Egholm; Sherif R Zaki; James E Goldman; Hans D Ochs; W Ian Lipkin Journal: Emerg Infect Dis Date: 2010-06 Impact factor: 6.883
Authors: Samia N Naccache; Karl S Peggs; Frank M Mattes; Rahul Phadke; Jeremy A Garson; Paul Grant; Erik Samayoa; Scot Federman; Steve Miller; Michael P Lunn; Vanya Gant; Charles Y Chiu Journal: Clin Infect Dis Date: 2015-01-07 Impact factor: 9.079
Authors: Yosra A Helmy; Mohamed Fawzy; Ahmed Elaswad; Ahmed Sobieh; Scott P Kenney; Awad A Shehata Journal: J Clin Med Date: 2020-04-24 Impact factor: 4.241
Authors: Andrew B Janowski; Macee C Owen; Holly Dudley; Tomás López; Rafaela Espinosa; Memory Elvin-Lewis; Alejandro Colichon; Carlos F Arias; Peter D Burbelo; David Wang Journal: mSphere Date: 2021-09-01 Impact factor: 4.389